Allergan: An Undervalued Pharma Company; Focusing On The Fundamentals While Activists And Management 'Duke It Out' [Seeking Alpha]
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Seeking Alpha
Allergan: An Undervalued Pharma Company; Focusing On The Fundamentals While Activists And Management 'Duke It Out' Summary Allergan’s medical aesthetics business to benefit from strong brands in a growing and underpenetrated cash-pay segment of the industry. In our view, pipeline expectations are set fairly low, providing an easier hurdle to be cleared. Management is looking for ~1-2 launches per year for the next several years. We view recent headwinds as already baked into the stock price with AGN trading at just ~9.2x trailing ex-items earnings vs. the broader S&P 500 trading at ~18.5x. At Kays Financial, we recently added Allergan ( To start with medical aesthetics, we see this as a growing and resilient business with high barriers to entry. In FY'18, medical aesthetics grew ~13% YOY to $4.3B and made up a substantial ~27% of revenues. Segments of the business can be broadly categorized as facial aesthetics, plastic surgery, regenerative medicine and body contouring, with their la
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]Yahoo! Finance
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingBusiness Wire
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
RVNC
Earnings
- 2/28/24 - Beat
RVNC
Sec Filings
- 4/9/24 - Form SC
- 3/21/24 - Form DEFA14A
- 3/21/24 - Form DEF
- RVNC's page on the SEC website